Lonza Benelux

Foundation date

1897

Sector

#Biotechnology / R&D Services

Subsector

Lonza is one of the world’s largest companies for contract development and manufacturing, recognized for reliable, high-quality services, regulatory track record, global footprint, innovative technology platforms and over 35 years of experience in mammalian cell culture.

Lonza customers need to maintain high productivity, product quality and reproducibility when moving from the research phase into clinical and commercial manufacturing, rapidly bringing candidates to the clinic and products to market. A successful outcome will often require significant technical expertise and advanced development and manufacturing technologies.

In Lonza’s extensive contract development and manufacturing services portfolio, Lonza uses advanced technologies to quickly and efficiently deliver products such as monoclonal antibodies, complex proteins and recombinant proteins. Their biologics offering spans from preclinical services, clinical drug product and drug substance and commercial supply in Mammalian, Microbial, ADCs / Bioconjugates, mRNA and Cell & Gene Therapies.

Lonza works in partnership with customers of all sizes, from start-ups to large biotechs and pharmaceutical companies, and can tailor our products and services to your specific needs, budget and timelines

Upcoming events

Latest news

  • V-Bio Ventures leads €20 million Series A financing of Precision oncology company Flindr Therapeutics to advance first-in-class small molecule inhibitors

    Wednesday April 24th 2024

  • Labconsort and NEKTARI join forces for a more sustainable and social industry

    Saturday April 20th 2024

  • BIO INX Complements Advisory Board with Distinguished Industry Leaders

    Thursday April 18th 2024